Table 2 Toxicity and antiviral activity of lectins

AH

No

No

HIV-1 (2–110), HIV-2 (3–14),

[148, 157,158,159,160,161,162,163,164]

CV-N

Yes

Yes

HIV (0.1–33.7), HCV (1.6), Ebo (100)

[34,35,36,37,38,39,40]

MVN

No

No

HIV-1 (2–167), HCV (31–39)

[50, 51]

MVL

Yes

Unk

HIV-1 (30–37), HCV (14–34)

[188, 189]

SVN

No

Unk

HIV-1 (0.3–22), EBOV (41)

[190,191,192,193,194]

OAA

Yes

Unk

HIV-1 (30–45)

[56, 57]

PRM-A

No

No

HIV-1/2 (1.6-10 µM), SIV (5 µM)

[62, 63]

GRFT

No

No

HIV (0.03–1.3), HCV (6.7–13.9), SARS-Cov (48), JEV (20), HSV-2(230), HPV (0.4–1.39 µM), NiV (20–60), ANDV (180–230)

[104,105,106,107,108,109, 113,114,115,116,117,118,119,120,121,122,123,124, 178, 195, 196]

BCA

No

Unk

HIV-1 (8.2), influenza H3N2 (18.8–74.2)

[64]

BanLec

Yes

Yes

HIV-1 (0.8–14), HIV-2 (3.7)

[171,172,173,174]

GNA

No

Unk

HCV (11.1–25.5), influenza A H1N1 (0.1–268), influenza A H3N2 (0.4–6.4), influenza B (0.016–0.89), HIV-1 (0.3–4.7 μg/ml), HIV-2 (0.1–0.2 μg/ml), SIV (2.7 μg/ml), FIV (0.09 μg/ml), SARS-COV (6.2 μg/ml), FIPV (3.9 μg/ml)

[130,131,132,133,134]

HHA

No

Unk

Influenza A H1N1 (0.05–121), influenza A H3N2 (0.10–3), influenza B (0.015–1.8), HIV-1 (0.3–3.2 μg/ml), HIV-2 (0.1–0.2 μg/ml), SIV (0.6 μg/ml), FIV (0.1 μg/ml), SARS-COV (3.2 μg/ml), FIPV (2.6 μg/ml)

[130,131,132,133,134]

PCL

No

Unk

HIV-1 (0.05–0.08 μg/ml), HIV-2 (0.08–0.1 μg/ml)

[179, 197]

UDA

Yes

Yes

HIV-1(100–180), HIV-2 (240–420), HSV-1(9.6- > 11 µM), HSV-2 (1.1–1.3 µM), SIV (130–190), MSV (> 20 µg/ml), SARS-CoV (0.9–2.6 µg/ml), influenza A H1N1 (5–435), influenza A H3N2 (5.8–83), and influenza B (0.64–14)

[182,183,184,185,186,187, 198,199,200,201,202,203]

NICTABA

No

Unk

HSV-1 (171–263), HSV-2 (41–64), influenza A H1N1 (21–43), influenza A H3N2 (13–23), influenza B (11), RSV (105), and DENV type 2 (323–729)

[107, 176,177,178]

PHA

No

Yes

SARS-CoV-2 (141–217.9), HIV-1 (50 µg/ml)

[116, 122]

LCA

No

Unk

SARS-CoV-2 (152.3–186.6)

[116]

SVL

No

Unk

HIV-1 (2.8 µM)

[14]

CGL

No

Yes

HIV-1 (2.5 µM)

[14]